Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed)

Active
No
Status
Posted
Published Date
February 14th, 2024
Close Date
April 17th, 2024
Opportunity No.
RFA-AA-24-003

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Limited Competition: Collaborative Study on the Genetics of Alcoholism (COGA) (U10 Clinical Trial Not Allowed)". This opportunity falls under the category of Health and is a discretionary grant. The funding instrument type for this opportunity is a Cooperative Agreement. The CFDA number associated with this grant is 93.307. The purpose of this grant is to identify genetic variants that affect the susceptibility to develop alcohol use disorder (AUD). The grant aims to advance the understanding of the complexity of the genotypes and phenotypes that contribute to the heterogeneity of AUD. It also seeks to integrate the analysis of multiple data sources and generate mechanistic hypotheses to understand the contributions of genetic, behavioral, and environmental factors on the development of or resilience from AUD. This limited competition notice of funding opportunity (NOFO) is specifically soliciting a cooperative agreement (U10) application from investigators who are currently supported under an existing study called Collaborative Study on the Genetics of Alcoholism (COGA). The grant does not require cost sharing or matching. Small businesses and other eligible applicants are invited to apply. However, non-domestic (non-U.S.) entities and non-domestic components of U.S. organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are also not allowed. The deadline for submitting applications is April 17, 2024. For more information and to apply, please visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-003.html. If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.

Description

This notice of funding opportunity (NOFO) is a limited competition notice of funding opportunity (NOFO) soliciting a cooperative agreement (U10) application from investigators currently supported under an existing study, entitled Collaborative Study on the Genetics of Alcoholism (COGA). The purpose of COGA is to identify genetic variants that affect the susceptibility to develop alcohol use disorder. The goals of this limited competition are to continue to advance the understanding of the complexity of the genotypes and phenotypes that contribute to the heterogeneity of AUD, integrate the analysis of multiple data sources, and generate mechanistic hypothesis to understand the contributions of genetic, behavioral, and environmental factors on the development of (or resilience from) AUD.

Contact Information

Attachments
0 KB

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)". This grant is in the category of Health and falls under the funding instrument type of Grant. The purpose of this grant is to support an integrated, broad-based multidisciplinary, multi-investigator, long-term program of research and research support activities planned around a specific major research theme related to alcohol research. The grant does not require any cost sharing or matching requirement. The maximum award ceiling for this grant is $1,250,000. The eligibility for this grant is open to various types of applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), U.S. Territory or Possession. However, Non-domestic (non-U.S.) Entities (Foreign Organization) and non-U.S. components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. The closing date for this grant opportunity is November 15, 2024, and the archive date is December 21, 2024. For more information and to apply, please visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-008.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-AA-24-008.html). If you have any inquiries, you can contact NIH Grants Information at grantsinfo@nih.gov.
Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional)". This grant aims to support Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol-associated organ damage (AAOD). The grant seeks eligible applicants who have identified a therapeutic candidate with a robust body of background data in the basic science and early discovery phases, ready for transition to the preclinical and clinical phases of development. The candidate should possess favorable properties such as bioactivity, stability, manufacturability, bioavailability, in vivo efficacy, and target engagement consistent with the desired clinical application. Projects responsive to this announcement can be at any point along the drug development continuum, from late discovery to early-stage clinical trials. For small molecules, eligibility requires having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD is allowed as the earliest entry point. The ultimate goal of this grant is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be tailored to the proposed project. While early-phase clinical trials are supported, they are not mandatory. Small disadvantaged and women-owned small businesses are encouraged to apply. For more information and to apply, please visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html](http://grants.nih.gov/grants/guide/pa-files/PAR-22-102.html). If you have any inquiries, please contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.